1. Development of Traceable Mouse Models of Advanced and Metastatic Bladder Cancer.
- Author
-
Desponds, Emma, Kioseoglou, Konstantina, Zdimerova, Hana, Ongaro, Marco, Verdeil, Grégory, and Leblond, Marine M.
- Subjects
- *
BIOLOGICAL models , *TRANSGENIC animals , *RESEARCH funding , *IMMUNOTHERAPY , *ANIMALS , *IN vivo studies , *MANN Whitney U Test , *METASTASIS , *GENE expression , *MICE , *IMMUNOHISTOCHEMISTRY , *CELL lines , *IMMUNE checkpoint inhibitors , *ANIMAL experimentation , *ONE-way analysis of variance , *GENETIC mutation , *TUMOR antigens , *DISEASE progression ,BLADDER tumors - Abstract
Simple Summary: Poor prognosis for advanced bladder cancer underlines the need for a better understanding of tumor resistance to treatment in relevant preclinical models. We developed new models of inducible and orthotopic muscle-invasive bladder cancer, with strong phenotypical and genetic resemblances to the human disease. These models enable real-time tracking of tumor progression and metastasis through bioluminescence imaging to facilitates the testing of new therapies. This valuable tool is important for advancing bladder cancer research and developing more effective treatments. Bladder cancer (BC) is the fourth most common cancer in men, with a poor patient prognosis for advanced disease. The poor survival of patients with muscle-invasive bladder cancer (MIBC) and metastatic status emphasizes the urgent need to develop new therapies. Lacking in the field of BC is the availability of relevant advanced BC mouse models, especially metastatic ones, that accurately recapitulate the complexities of human pathology to test and study new therapeutic strategies. Addressing this need, we developed a traceable mouse model of BC that expresses tumor-associated antigens within the context of advanced muscle-invasive BC. This novel system was achieved through the deletion of the tp53 and pten genes, alongside the incorporation of the fusion construct of Firefly luciferase (Luc) and the SIYRYYGL (SIY) T-cell antigen. We validate that the presence of the transgene did not impact on the development of the tumors while allowing us to measure tumor progression by bioluminescence. We show that the transgene did not influence the composition of the immune tumor microenvironment. More importantly, we report that this model was unresponsive to anti-PD-1 treatment, as in the majority of patients with BC. We also develop a new model based on the orthotopic injection of BC clonal cell lines derived from our first model. We demonstrate that this new model invades the muscle layer and has a metastasis development rate of 83%. The advantage of this model is that we can visualize tumor growth and metastasis development in vivo. These mouse models' characteristics, displaying many similarities with the human pathology, provide a valuable tool for tracking tumor progression, metastasis spread in vivo, and treatment resistance, as well as exploring fundamental and translational aspects of BC biology. This work contributes to the improvement in the landscape of mouse models of advanced BC for testing new therapeutic strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF